The FDA has approved Rybrevant (amivantamab) in combination with chemotherapy to treat advanced, EGFR-mutant NSCLC that progressed on or after treatment with an EGFR TKI.
(HealthDay News) — Among cancer survivors, excess body weight is associated with an increased risk of a second primary cancer, according to a study published in JAMA Network Open.
The US Food and Drug Administration (FDA) has approved a 420 mg dosage strength of Hercessi (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab). Hercessi, a HER2/neu receptor antagonist, is ...
Our easy-to-read fact sheets provide clinicians with reliable information to share with patients and their caregivers. Breast cancer is the most common cancer in women in the United States.